Table 3 Correlates of etanercept withdrawal after achieving inactive disease (multivariable model)
|  | Eta was not withdrawn by inactive disease, n = 1392 | Eta was withdrawn by inactive disease, n = 332 | HR | p value | 95% CI |
|---|---|---|---|---|---|
Female gender | 945 (67.9%) | 201 (60.5%) | 0.96 | 0.749 | 0.73 to 1.25 |
Age, years, mean (SD) | 13.7 (3.5) | 11.9 (3.1) | 0.92 | < 0.001 | 0.89 to 0.96 |
ANA positive | 589 (42.5%) | 128 (38.7%) | 0.82 | 0.148 | 0.62 to 1.07 |
HLA-B27 positive | 368 (26.6%) | 104 (31.4%) | 1.10 | 0.57 | 0.78 to 1.55 |
JIA categories | |||||
 Systemic JIA | 96 (6.9%) | 15 (4.5%) | 0.83 | 0.512 | 0.47 to 1.45 |
 Polyarticular arthritis, RF-negative | 386 (27.7%) | 101 (30.4%) | 1.08 | 0.572 | 0.83 to 1.39 |
 Polyarticular arthritis RF-positive | 156 (11.2%) | 20 (6.0%) | 0.56 | 0.014 | 0.35 to 0.89 |
 Persistent Oligoarthritis | 48 (3.5%) | 25 (7.5%) | 1.89 | 0.004 | 1.22 to 2.93 |
 Extended Oligoarthritis | 247 (17.7%) | 60 (18.1%) | 1.08 | 0.648 | 0.79 to 1.47 |
 Enthesitis-related arthritis | 286 (20.6%) | 73 (22.0%) | 1.24 | 0.197 | 0.89 to 1.71 |
 Psoriatic arthritis | 126 (9.1%) | 22 (6.6%) | 0.89 | 0.582 | 0.59 to 1.35 |
 Duration between JIA onset and bDMARD start, in months, mean (SD) | 60.8 (48.5) | 46.0 (38.3) | 0.91 | < 0.001 | 0.87 to 0.95 |
c-JADAS-10 | |||||
 At therapy start | 15.1 (6.7) | 14.5 (6.5) | 0.9 | < 0.001 | 0.86 to 0.93 |
 Therapy response within the first 6 months | 9.3 (6.6) | 11.3 (6.6) | 1.12 | < 0.001 | 1.07 to 1.16 |